Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial

Mukohara, T; Park, YH; Sommerhalder, D; Yonemori, K; Hamilton, E; Kim, SB; Kim, JH; Iwata, H; Yamashita, T; Layman, RM; Mita, M; Clay, T; Chae, YS; Oakman, C; Yan, F; Kim, GM; Im, SA; Lindeman, GJ; Rugo, HS; Liyanage, M; Saul, M; Le Corre, C; Skoura, A; Liu, L; Li, M; LoRusso, PM

Author(s): Mukohara, T; Park, YH; Sommerhalder, D; Yonemori, K; Hamilton, E; Kim, SB; Kim, JH; Iwata, H; Yamashita, T; Layman, RM; Mita, M; Clay, T; Chae, YS; Oakman, C; Yan, F; Kim, GM; Im, SA; Lindeman, GJ; Rugo, HS; Liyanage, M; Saul, M; Le Corre, C; Skoura, A; Liu, L; Li, M; LoRusso, PM;
Details: Publication Year 2024-08,Volume 30,Issue #8,Page 2242-2250
Journal Title: Nature Medicine
Publication Type: Research article
Abstract: Inhibition of histone lysine acetyltransferases (KATs) KAT6A and KAT6B has shown antitumor activity in estrogen receptor-positive (ER(+)) breast cancer preclinical models. PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B. In the present study, we report the safety, pharmacokinetics (PK), pharmacodynamics, efficacy and biomarker results from the first-in-human, phase 1 dose escalation and dose expansion study (n = 107) of PF-07248144 monotherapy and fulvestrant combination in heavily pretreated ER(+) human epidermal growth factor receptor-negative (HER2(-)) metastatic breast cancer (mBC). The primary objectives of assessing the safety and tolerability and determining the recommended dose for expansion of PF-07248144, as monotherapy and in combination with fulvestrant, were met. Secondary endpoints included characterization of PK and evaluation of antitumor activity, including objective response rate (ORR) and progression-free survival (PFS). Common treatment-related adverse events (any grade; grades 3-4) included dysgeusia (83.2%, 0%), neutropenia (59.8%, 35.5%) and anemia (48.6%, 13.1%). Exposure was approximately dose proportional. Antitumor activity was observed as monotherapy. For the PF-07248144-fulvestrant combination (n = 43), the ORR (95% confidence interval (CI)) was 30.2% (95% CI = 17.2-46.1%) and the median PFS was 10.7 (5.3-not evaluable) months. PF-07248144 demonstrated a tolerable safety profile and durable antitumor activity in heavily pretreated ER(+)HER2(-) mBC. These findings establish KAT6A and KAT6B as druggable cancer targets, provide clinical proof of concept and reveal a potential avenue to treat mBC. clinicaltrial.gov registration: NCT04606446 .
Publisher: Springer Nature
Keywords: Humans; Female; *Breast Neoplasms/drug therapy/pathology/genetics; *Histone Acetyltransferases/antagonists & inhibitors/genetics/metabolism; Middle Aged; *Receptor, ErbB-2/metabolism/genetics; *Receptors, Estrogen/metabolism; *Fulvestrant/therapeutic use/administration & dosage; Aged; Adult; Neoplasm Metastasis; Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects
Department(s): Medical Oncology
Publisher's Version: https://doi.org/10.1038/s41591-024-03060-0
Open Access at Publisher's Site: https://doi.org/10.1038/s41591-024-03060-0
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-09-19 02:59:43

Last Modified: 2024-09-19 03:00:01